This complimentary program is geared toward U.S. companies expanding or starting business in China as well as U.S. private equity funds looking to expand their investment portfolios by acquiring equity interests in Chinese companies.
During this interactive session, panelists will discuss the common pitfalls of and practical strategies for doing business in China, including:
- Current trends impacting U.S. companies investing and doing business in China
- Special issues involved in acquiring equity interests in Chinese companies
- China’s foreign exchange control regulations and what they mean to U.S. companies in China
- Considerations on capital structure and available financing options for investments in China
- Managing employer-employee relationships in China
- Challenges of and opportunities arising from the current economic situations in the United States and China
Featured Speakers:
- H. Timothy Lopez, A.O. Smith, Associate General Counsel
- Kok-Chi Tsim, JPMorgan Chase, Managing Director and Senior Relationship Executive
- Z. Julie Lee, Foley International Business Transactions Partner
- Barry L. Grossman (Moderator), Foley Intellectual Property Of Counsel
Co-Sponsor:
People
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.